Scholarlink

<p>Diabetic retinopathy (DR), the most prevalent ocular complication of diabetes, progresses from non-proliferative (NPDR) to sight-threatening proliferative (PDR) stages. Current interventions—including retinal photocoagulation, intravitreal anti-VEGF agents, and surgery—address advanced disease, often require repeated administration, and carry risks like retinal injury. Safer, more effective, and longer-lasting treatments are needed, especially for early-stage DR. Mesenchymal stem cells (MSCs) and their derivatives offer a promising alternative, with advantages including low immunogenicity, paracrine signaling, and the ability to mitigate inflammation and vascular permeability. However, challenges in delivery efficiency and targeting specificity remain. Hydrogel-based scaffold materials are increasingly important due to their superior biocompatibility and ability to overcome ocular barriers. Recent advances include novel injectable hydrogels that can be combined with drugs or stem cells, enabling targeted delivery to retinal layers, prolonging therapeutic retention, and significantly improving bioavailability for sustained treatment of DR.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Hydrogel-based delivery of MSCs and derivatives for improved diabetic retinopathy therapy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月20日

查看全文
  • Ludan Sun,
  • Yuanyuan Qi,
  • Yumeng Zhang,
  • Zhijian Zhang,
  • Zhe Fan,
  • Chuanfeng An,
  • Lijun Zhao,
  • Lijun Zhang

摘要

Diabetic retinopathy (DR), the most prevalent ocular complication of diabetes, progresses from non-proliferative (NPDR) to sight-threatening proliferative (PDR) stages. Current interventions—including retinal photocoagulation, intravitreal anti-VEGF agents, and surgery—address advanced disease, often require repeated administration, and carry risks like retinal injury. Safer, more effective, and longer-lasting treatments are needed, especially for early-stage DR. Mesenchymal stem cells (MSCs) and their derivatives offer a promising alternative, with advantages including low immunogenicity, paracrine signaling, and the ability to mitigate inflammation and vascular permeability. However, challenges in delivery efficiency and targeting specificity remain. Hydrogel-based scaffold materials are increasingly important due to their superior biocompatibility and ability to overcome ocular barriers. Recent advances include novel injectable hydrogels that can be combined with drugs or stem cells, enabling targeted delivery to retinal layers, prolonging therapeutic retention, and significantly improving bioavailability for sustained treatment of DR.

Graphical Abstract